Earnings summaries and quarterly performance for Nurix Therapeutics.
Executive leadership at Nurix Therapeutics.
Board of directors at Nurix Therapeutics.
Research analysts covering Nurix Therapeutics.
Recent press releases and 8-K filings for NRIX.
Nurix Therapeutics Provides Update on Degrader Pipeline and Clinical Trials
NRIX
New Projects/Investments
Guidance Update
- Nurix Therapeutics is advancing its lead targeted protein degrader, Bexobrutideg, for oncology and autoimmune diseases, with a Phase 3 randomized confirmatory trial for CLL planned to start in the first half of 2026.
- Bexobrutideg differentiates from inhibitors by completely removing the BTK protein, addressing resistance mutations, and demonstrating a clean proteomic profile with 64-fold selectivity over TEC, which is associated with cardiovascular side effects.
- The company will present new data on Bexobrutideg at the upcoming ASH meeting, including duration of effect, progression-free survival, and the selection of the 600 mg once-daily dose for pivotal studies.
- Nurix estimates the total CLL market for BTK targeted agents to be $9.5 billion per year, with approximately 10,000 new second-line patient prescriptions and 6,000 third-line plus annually in the U.S..
- In its autoimmune pipeline, Nurix is developing a STAT6 degrader (NX3911) with Sanofi, projected for IND filing in 2026, and an IRAK4 degrader with Gilead, currently in Phase 1, with potential data release in 2026.
1 day ago
Nurix Therapeutics Updates on Pipeline Progress and Clinical Trials
NRIX
New Projects/Investments
Guidance Update
- Nurix Therapeutics' lead program, Bexobrutadeg, a BTK degrader, is in pivotal studies for CLL, with a phase three randomized confirmatory trial planned to start in the first half of 2026.
- Bexobrutadeg demonstrates superior selectivity and mutational coverage, including 64-fold selectivity against TEC, a kinase associated with cardiovascular side effects, compared to competitor compounds.
- The company will present new data on Bexobrutadeg at the upcoming ASH meeting, including duration of effect, progression-free survival, and support for the 600 mg once daily dose chosen for pivotal studies.
- Nurix is advancing partnered programs, including a STAT6 degrader (NX3911) with Sanofi in IND enabling studies, with initial clinical development expected in 2026, and an IRAK4 degrader with Gilead in phase one, with potential phase 1 data release in 2026.
- The company highlights a substantial market opportunity in CLL, with the total marketplace for BTK targeted agents valued at $9.5 billion per year and approximately 10,000 new second-line patient prescriptions/starts annually in the US.
1 day ago
Nurix Therapeutics Provides Updates on Clinical Programs and Financial Position
NRIX
New Projects/Investments
Guidance Update
- Nurix Therapeutics (NRIX) plans to present follow-up and longer-term data for Bexobrutideg and NX-5948 at ASH, including duration of therapy and response from Phase 1A, and Phase 1B data. The 600 mg once-a-day dose for Bexobrutideg in CLL has been selected for the pivotal trial with FDA agreement.
- The initial pivotal study for Bexobrutideg in CLL will be a single-arm study targeting triple-exposed patients for accelerated approval, with a broader randomized controlled study planned for the second-line setting.
- The company is developing a new formulation of Bexobrutideg for autoimmune diseases, with an IND anticipated in 2026, and sees significant potential in neuroinflammatory diseases like MS due to its CNS activity.
- Nurix's partnered pipeline includes the IRAK4 degrader (GS-6791) with Gilead in Phase 1 (data expected 2026) and the STAT6 degrader (NX-3911) with Sanofi in IND enabling studies, with valuable opt-in rights for Nurix.
- Nurix recently raised $250 million, bringing its cash reserves to over $650 million and extending its financial runway through the beginning of 2028.
Nov 19, 2025, 11:00 AM
Nurix Therapeutics Details ASH 2025 Data, Pipeline Progress, and Financial Position
NRIX
Product Launch
New Projects/Investments
Guidance Update
- Nurix Therapeutics will present longer-term data for bexobrutideg and NX-5948 at ASH 2025, including duration of response and PFS, with patients on therapy for over two years. The 600 mg once-a-day dose of bexobrutideg has been selected for its pivotal CLL trial with FDA agreement.
- The company is pursuing accelerated approval for bexobrutideg in CLL for triple-exposed patients, with a subsequent randomized control study planned for full approval in the second-line setting, targeting a market of over 10,000 patients per year.
- Nurix's partnered pipeline includes the IRAK4 degrader (GS-6791) with Gilead in Phase I (data expected in 2026) and the STAT6 degrader (NX-3911) with Sanofi in IND-enabling studies, with Nurix holding valuable opt-in rights for co-development and co-commercialization.
- The company's cash reserves stand at over $650 million following a recent $250 million raise, providing a financial runway through the beginning of 2028.
Nov 19, 2025, 11:00 AM
Nurix Therapeutics Advances Bexdeg in CLL and Strengthens Financial Position
NRIX
New Projects/Investments
Guidance Update
- Nurix Therapeutics has initiated pivotal trials for Bexobrutideg (Bexdeg) in Chronic Lymphocytic Leukemia (CLL), demonstrating an 80% response rate in patients with four prior lines of therapy, and selected a 600 mg dose for its accelerated approval trial. A confirmatory Phase III trial is planned for initiation in H1 2026.
- The company will present updated data on Bexdeg at ASH, focusing on duration of response/progression-free survival and further justification for the 600 mg dose.
- Nurix reported a strong financial position with over $650 million in cash, providing a runway through the end of 2027 into 2028, bolstered by a recent $250 million offering.
- Other pipeline advancements include establishing mechanistic proof of concept for the CBL-B program in colorectal and prostate cancer, and progress in partnered programs with Sanofi (STAT6 degrader, expected in healthy volunteers in 2026) and Gilead (IRAK4 degrader in MAD studies).
Nov 13, 2025, 2:20 PM
Nurix Therapeutics Initiates Pivotal DAYBreak Clinical Trial for Bexobrutideg
NRIX
Product Launch
New Projects/Investments
- Nurix Therapeutics, Inc. has initiated the DAYBreak clinical trial, a pivotal single-arm Phase 2 study of bexobrutideg (NX-5948) for patients with relapsed or refractory chronic lymphocytic leukemia (r/r CLL).
- The 600 mg once daily oral dose of bexobrutideg has been cleared by global regulators, including the U.S. FDA, U.K. MHRA, and European Medicines Agency, for pivotal monotherapy trials.
- The DAYBreak study, with its first site activated in October 2025, aims to generate data to support a potential Accelerated Approval submission.
- Nurix plans to initiate a randomized confirmatory Phase 3 trial and a Phase 1b/2 combination study for bexobrutideg in the first half of 2026.
- New preclinical data support bexobrutideg's potential best-in-class BTK degrader profile, demonstrating superior degradation potency, broad coverage of BTK mutations, and exquisite selectivity.
Oct 22, 2025, 1:04 PM
Neurix Initiates Pivotal Trials for BexDeg in CLL and Secures Regulatory Alignment
NRIX
New Projects/Investments
Guidance Update
- Neurix (NRIX) has initiated pivotal trials for its lead program, bexorbitodec (BexDeg), in Chronic Lymphocytic Leukemia (CLL).
- The company has achieved regulatory alignment with the FDA, MHRA, and EMA on a 600 mg once-daily dose for BexDeg in registrational trials, selected for maximizing efficacy while maintaining safety.
- The first pivotal trial, the Daybreak Study, a single-arm Phase II study for potential accelerated approval in approximately 100 patients with relapsed/refractory CLL, has commenced.
- Neurix reported new preclinical data for its partnered STAT6 and IRAK4 programs, with potential for 50/50 co-development/commercialization in the US.
- Following a registered direct offering, Neurix's pro forma cash balance is anticipated to be $678 million, providing an expected runway into 2028.
Oct 22, 2025, 12:00 PM
Nurix Provides Update on Clinical Pipeline and Bexobrutideg Trials
NRIX
New Projects/Investments
- Nurix's lead program, Bexobrutideg (NX-5948), a BTK degrader, has initiated a Pivotal Phase 2 trial (DAYBreak CLL-201) for relapsed/refractory CLL, with the 600 mg once daily oral dose cleared by global regulators including the FDA, MHRA, and EMA.
- A Confirmatory Phase 3 trial for Bexobrutideg is planned for initiation in H1 2026 for 2L+ CLL patients who progressed on prior covalent BTK inhibitor.
- Bexobrutideg demonstrates a best-in-class profile with superior BTK degradation potency, mutational coverage, and selectivity compared to other BTK degraders and inhibitors.
- The partnered program, NX-0479/GS-6791 (IRAK4 degrader), initiated Phase 1 in Q2 2025 in collaboration with Gilead Sciences for rheumatoid arthritis and other inflammatory diseases.
- Nurix is also advancing NX-3911 (STAT6 degrader) for Type 2 inflammatory diseases, which has demonstrated activity in atopic dermatitis and asthma models.
Oct 22, 2025, 12:00 PM
Nurix Therapeutics Initiates Pivotal Trials for Vexer-Brutideg and Provides Pipeline Updates
NRIX
New Projects/Investments
Guidance Update
- Nurix Therapeutics has initiated pivotal trials for its lead program, Vexer-Brutideg (Vexdeg), in Chronic Lymphocytic Leukemia (CLL).
- Regulatory alignment has been secured for a 600 mg once-daily dose of Vexdeg for registrational trials, and the Daybreak study, a single-arm, phase 2 trial in approximately 100 patients with relapsed refractory CLL, has initiated for potential accelerated approval.
- The company plans to initiate a confirmatory phase 3 randomized trial and a combination basket study in CLL in the first half of 2026.
- New preclinical data was shared for partnered INI pipeline programs, STAT-6 (NX-3911) with Sanofi and IRAK4 (GS-6791) with Gilead Sciences, with potential opt-in opportunities in 2026.
- Nurix reported a pro forma cash balance of $678 million, providing an expected runway into 2028.
Oct 22, 2025, 12:00 PM
Nurix Therapeutics Reports Q3 2025 Financial Results and Clinical Development Plans
NRIX
Earnings
New Projects/Investments
Guidance Update
- Nurix Therapeutics reported a net loss of $86.4 million, or ($1.03) per share, on revenue of $7.9 million for the third quarter ended August 31, 2025.
- As of August 31, 2025, the company maintained a strong financial position with $428.8 million in cash, cash equivalents, and marketable securities.
- The company announced plans to initiate pivotal trials for bexobrutideg in relapsed/refractory CLL patients in the second half of 2025, with a strategy for potential accelerated approval.
- Preclinical data for GS-6791, a novel IRAK4 degrader developed in collaboration with Gilead, was presented at EADV 2025, demonstrating potent pathway inhibition and efficacy in a dermatitis model.
Oct 9, 2025, 8:02 PM
Quarterly earnings call transcripts for Nurix Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track Nurix Therapeutics's earnings for you
Get instant analysis when filings drop